Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2018-08-03 Tx date 2018-08-01 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-35,400
-236,000 vol $0.15 each |
1,307,250 | |
Filed 2017-12-15 Tx date 2017-12-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-20,500
-50,000 vol $0.41 each |
1,643,250 | |
Filed 2017-12-15 Tx date 2017-12-13 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-70,000
-100,000 vol $0.70 each |
1,543,250 | |
Filed 2017-12-15 Tx date 2017-12-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-23,000
-50,000 vol $0.46 each |
1,693,250 | |
Filed 2017-11-08 Tx date 2017-11-06 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-18,275
-107,500 vol $0.17 each |
1,743,250 | |
Filed 2017-09-12 Tx date 2017-09-10 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Options
50 - Grant of options
|
+200,000 vol |
200,000 | |
Filed 2017-09-12 Tx date 2015-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-09-12 Tx date 2017-09-11 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-6,750
-45,000 vol $0.15 each |
36,159 | |
Filed 2017-08-23 Tx date 2015-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-08-23 Tx date 2017-08-21 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Holder: Jim Irving Consulting (Indirect Ownership)
|
Common Shares
46 - Compensation for services
|
$6,995
+81,159 vol $0.0862 each |
81,159 | |
Filed 2017-06-21 Tx date 2017-06-15 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-48,000
-300,000 vol $0.16 each |
1,850,750 | |
Filed 2017-06-15 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
2,150,750 | |
Filed 2017-06-14 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
||
Filed 2017-06-14 Tx date 2017-06-12 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$92,500
+500,000 vol $0.185 each |
1,650,750 | |
Filed 2017-04-15 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$75,000
+500,000 vol $0.15 each |
||
Filed 2017-04-15 Tx date 2017-03-30 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,450
-45,000 vol $0.21 each |
||
Filed 2017-04-15 Tx date 2017-03-30 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,675
-45,000 vol $0.215 each |
705,750 | |
Filed 2017-04-15 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$93,000
+600,000 vol $0.155 each |
1,150,750 | |
Filed 2017-04-10 Tx date 2017-04-05 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$75,000
+500,000 vol $0.15 each |
1,050,750 | |
Filed 2017-04-03 Tx date 2017-03-31 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-31,000
-155,000 vol $0.20 each |
550,750 | |
Filed 2017-04-03 Tx date 2017-03-30 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,450
-45,000 vol $0.21 each |
705,750 | |
Filed 2017-04-03 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-6,900
-60,000 vol $0.115 each |
750,750 | |
Filed 2017-03-27 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
$90,000
+750,000 vol $0.12 each |
810,750 | |
Filed 2017-03-27 Tx date 2017-03-24 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,300
-60,000 vol $0.155 each |
60,750 | |
Filed 2016-12-22 Tx date 2016-12-19 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-18,450
-123,000 vol $0.15 each |
120,750 | |
Filed 2016-11-17 Tx date 2016-11-14 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
46 - Compensation for services
|
+43,750 vol |
243,750 | |
Filed 2016-10-24 Tx date 2015-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-10-24 Tx date 2016-10-14 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$45,000
+250,000 vol $0.18 each |
250,000 | |
Filed 2016-05-06 Tx date 2016-05-03 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,000
+100,000 vol $0.05 each |
200,000 | |
Filed 2016-04-13 Tx date 2015-11-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,000
+100,000 vol $0.09 each |
100,000 | |
Filed 2016-04-13 Tx date 2015-09-16 |
$ATT
Abattis Bioceuticals Corp. |
Irving, James
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|